HOME >> BIOLOGY >> NEWS
Antibiotic treats lymphoma of the eye

The common antibiotic doxycycline effectively treats a type of lymphoma associated with chlamydia infection, according to a study in the October 4 issue of the Journal of the National Cancer Institute.

Ocular adnexal lymphoma of the MALT-type (OAL) is a kind of cancer of the eyelids and related tissues. It is not often fatal, but its symptoms can compromise a patient's quality of life. Some research has suggested an association between OAL and infection with the bacteria Chlamydia psittaci.

Andres J. M. Ferreri, M.D., of the San Raffaele H Scientific Institute in Milan, Italy, and colleagues examined whether doxycycline was an effective treatment for OAL. They gave 27 OAL patients a 3-week course of doxycycline therapy, whether they were positive or negative for chlamydia. They looked for tumor progression every 6 months.

The authors found that doxycycline treatment caused lymphoma to regress in both patients who did not test positive for the disease and those who did. They suggest that doxycycline may be a useful therapy even in patients where other treatments have failed, and it is a valid alternative to chemotherapy and radiation without causing the same toxic side-effects. Patients treated with doxycycline had a 66% rate of disease-free survival.

"Our prospective trial revealed that doxycycline is a fast, safe, and active treatment for OAL, both at initial diagnosis and at relapse," the authors write.

In an accompanying editorial, Emanuel Zucca, M.D., and Francesco Bertoni, M.D., of the Oncology Institute of Southern Switzerland, write, "While doxycycline appears to be an easy-to-implement therapeutic approach, we strongly encourage all physicians to enroll patients in clinical prospective trials to help answer these questions."


'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
3-Oct-2006


Page: 1

Related biology news :

1. Antibiotic stress, genetic response and altered permeability of E. coli
2. Antibiotic inhibits cancer gene activity
3. Antibiotic resistance markers in GM plants not a risk to human health
4. Antibiotics may not be enough to stop recurrent gastric lymphoma caused by Helicobacter pylori
5. Antibiotics help combat dangerous tropical disease
6. Antibiotic resistant bacterium uses Sonar-like strategy to see enemies or prey
7. Antibiotic-resistant bacteria increased after clindamycin use for common vaginal infection
8. Antibiotic identified as potential anti-cancer candidate
9. Stem cell procedure successfully treats amyloidosis patients
10. New compound effectively treats fungal infections
11. Gene therapy advance treats hemophilia in mouse models

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antibiotic treats lymphoma the eye

(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
(Date:3/10/2015)... 2015 Transforming How We Look ... Medicine in Human Space Flight" by Michael ... , Ph.D. was recently featured by Springer Science Media, highlighting ... Specifically, "Personalized Medicine in Human Space Flight" ... in 2013 and 2014 from Springer in the journal ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received FDA ... adult men and women with androgenic alopecia (AGA) having ... IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... and under-deliver, FDA Clearance underscores the safety and efficacy ... than 80 million men and women who suffer with ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers declined ... prices in 2008. However, the situation has stabilised afterwards, ... momentum now. , To date, the world annual production ... tonnes. No considerable growth was registered in the market ... 2012-2013, registering 11% growth as against the period of ...
(Date:3/27/2015)... , 27. März 2015  Peter ... in Biomedical Science für seine bahnbrechende Arbeit ... zwischen Zellkompartimenten transportiert werden, sowie für die ... zur Reaktion auf Stress nutzen, der mit ... Walter ist Professor für Biochemie an der ...
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
Breaking Biology Technology:Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Neogen CEO adopts 10b5-1 Trading Plan 2
Cached News: